Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing

Nick Paul Taylor In this week's EuroBiotech Report, Metabomed celebrated adding Pfizer to a list of investors that already featured the VC units of Merck KGaA and Boehringer Ingelheim. ...

Harvard, Tufts med students stage protest at ‘biased’ $2.9B drug development figure

Ben Adams Around two dozen students from Harvard Medical School and Tufts University as well as members of health activist groups protested in front of the Tufts Center for the Study ...

Survey: Biopharma gets a bad grade on gender diversity

John Carroll The biopharma industry doesn't do a very good job when it comes down to the way it handles gender diversity. And if you're a woman in this business, chances are ...

Can fast-growing Eliquis overtake J&J’s Xarelto? Bristol’s execs think so

Carly Helfand Eliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has rocketed to the top of Bristol-Myers Squibb's sales charts. And company ...

Mapi Pharma swings for $50M haul as oft-delayed IPO nears D-Day

Nick Paul Taylor Mapi Pharma has set the terms for its latest crack at listing on Nasdaq. The biotech, which set terms on its first IPO attempt back in April 2014, is aiming to round ...

Amgen’s Humira biosim is one step closer to FDA approval. But how close is it to market?

Carly Helfand On Monday, Amgen said the FDA had accepted its application for its biosimilar of AbbVie's Humira, so-called ABP 501–but earlier this month, the U.S. Patent ...

Lawmaker to Martin Shkreli: Come to DC and take the 5th, in a live performance

John Carroll FierceBiotech News

U.K.’s NICE says yes to Opdivo for advanced skin cancer

Eric Palmer Last month the U.K. drug cost watchdog nixed Bristol-Myers Squibb's immunotherapy Opdivo for use against lung cancer, saying in draft guidance that it just cost too ...

Galapagos advances AbbVie-partnered CF drug; UCL forms £50M fund; Vasopharm bags €20M

Nick Paul Taylor In this week's EuroBiotech Report, the first of two correctors destined for use in Galapagos' triple-hit cystic fibrosis therapy is now in the clinic. With ...

U.K. competition watchdog targets pharma for ‘substantial fines’

Emily Wasserman The U.K.'s Competition and Markets Authority (CMA) is planning to levy "substantial fines" this year, marking a "big step up in the scale and impact" ...

Flailing MannKind makes a murky move to stay afloat, signing away pipeline drugs

Damian Garde MannKind, decimated by the departure of former co-signer Sanofi, is trying to conserve value in the face of sluggish sales for its inhaled insulin, signing a deal to transfer ...

Bristol-Myers moves forward with its $1.2B CytomX alliance

Damian Garde Bristol-Myers Squibb, working alongside CytomX Therapeutics, picked a third cancer project in a collaboration that could pay its partner as much as $ 1.2 billion. FierceBiotech ...
Page 1 of 17312345...102030...Last »
© 2016 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS